Lipoprotein (a): where does the atherogenicity reside?

Editorial

Lars Berglund. J Lab Clin Med. 2002 Mar.

. 2002 Mar;139(3):131-2.

doi: 10.1067/mlc.2002.121769.

No abstract available

Comment on

Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart disease.
Martín S, Pedro-Botet J, Joven J, Simó JM, Ladona MG, Pavesi M, Rubiés-Prat J. Martín S, et al. J Lab Clin Med. 2002 Mar;139(3):181-7. doi: 10.1067/mlc.2002.121770. J Lab Clin Med. 2002. PMID: 11944029

Lipoprotein(a)-lowering therapies: a double edged sword?
Lippi G. Lippi G. Atherosclerosis. 2015 Oct;242(2):504-5. doi: 10.1016/j.atherosclerosis.2015.08.018. Epub 2015 Aug 14. Atherosclerosis. 2015. PMID: 26298742 No abstract available.
Genetic basis for multimodal relationship between apolipoprotein (a) size and lipoprotein (a) concentration in Mexican-Americans.
Rainwater DL. Rainwater DL. Atherosclerosis. 1995 Jun;115(2):165-71. doi: 10.1016/0021-9150(94)05507-f. Atherosclerosis. 1995. PMID: 7661875
Lipoprotein(a) plasma levels and apo(a) isoforms are not associated with longevity or disability in a sample of Italian octo-nonagenarians. Associazione Medica Sabin.
Zuliani G, Bader G, Imbastaro T, Mezzetti A, Taddeo U, Kostner GM, Fellin R. Zuliani G, et al. Aging (Milano). 1995 Oct;7(5):385-91. doi: 10.1007/BF03324350. Aging (Milano). 1995. PMID: 8719606
Molecular genetics of lipoprotein (a): new pieces to the puzzle.
Gaw A, Hobbs HH. Gaw A, et al. Curr Opin Lipidol. 1994 Apr;5(2):149-55. doi: 10.1097/00041433-199404000-00012. Curr Opin Lipidol. 1994. PMID: 8044418 Review.
Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk.
Nordestgaard BG, Tybjærg-Hansen A. Nordestgaard BG, et al. Curr Opin Lipidol. 2011 Apr;22(2):113-22. doi: 10.1097/MOL.0b013e32834477d2. Curr Opin Lipidol. 2011. PMID: 21358543 Review.